Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data | News Direct

Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data

Poolbeg Pharma PLC
News release by Poolbeg Pharma PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | March 02, 2023 05:59 AM Eastern Standard Time

 

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule.

 

Skillington says that he "couldn't be happier" with the results, that he says will help "ramp up the discussions" with potential partners.

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthPharmaBiotechLupusInfectious Diseases